Julie C. Frith

3.6k total citations · 2 hit papers
17 papers, 2.9k citations indexed

About

Julie C. Frith is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Julie C. Frith has authored 17 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Julie C. Frith's work include Bone health and treatments (14 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Bone Metabolism and Diseases (5 papers). Julie C. Frith is often cited by papers focused on Bone health and treatments (14 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Bone Metabolism and Diseases (5 papers). Julie C. Frith collaborates with scholars based in United Kingdom, Finland and United States. Julie C. Frith's co-authors include Michael J. Rogers, Jukka Mönkkönen, Helena L. Benford, Fraser P. Coxon, Steven P. Luckman, Sharon Gordon, Seppo Auriola, R.G.G. Russell, G. Michael Blackburn and C M Shipman and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Cancer and Journal of Bone and Mineral Research.

In The Last Decade

Julie C. Frith

17 papers receiving 2.8k citations

Hit Papers

Cellular and molecular mechanisms of action of bisphospho... 2000 2026 2008 2017 2000 2000 200 400 600

Peers

Julie C. Frith
Helena L. Benford United Kingdom
Steven P. Luckman United Kingdom
Mark W. Lundy United States
David Roodman United States
R. Graham United Kingdom
Ermond van Beek Netherlands
K J Ibbotson United States
Helena L. Benford United Kingdom
Julie C. Frith
Citations per year, relative to Julie C. Frith Julie C. Frith (= 1×) peers Helena L. Benford

Countries citing papers authored by Julie C. Frith

Since Specialization
Citations

This map shows the geographic impact of Julie C. Frith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie C. Frith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie C. Frith more than expected).

Fields of papers citing papers by Julie C. Frith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie C. Frith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie C. Frith. The network helps show where Julie C. Frith may publish in the future.

Co-authorship network of co-authors of Julie C. Frith

This figure shows the co-authorship network connecting the top 25 collaborators of Julie C. Frith. A scholar is included among the top collaborators of Julie C. Frith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie C. Frith. Julie C. Frith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Coxon, Fraser P., Julie C. Frith, Helena L. Benford, & Michael J. Rogers. (2003). Isolation and Purification of Rabbit Osteoclasts. Humana Press eBooks. 80. 89–100. 11 indexed citations
2.
McGowan, Neil, Heather MacPherson, Katrien Janssens, et al.. (2003). A Mutation Affecting the Latency-Associated Peptide of TGFβ1 in Camurati-Engelmann Disease Enhances Osteoclast Formationin Vitro. The Journal of Clinical Endocrinology & Metabolism. 88(7). 3321–3326. 28 indexed citations
3.
Staal, Ada, Julie C. Frith, M. H. French, et al.. (2003). The Ability of Statins to Inhibit Bone Resorption Is Directly Related to Their Inhibitory Effect on HMG-CoA Reductase Activity. Journal of Bone and Mineral Research. 18(1). 88–96. 144 indexed citations
4.
Frith, Julie C. & Michael J. Rogers. (2003). Antagonistic Effects of Different Classes of Bisphosphonates in Osteoclasts and Macrophages In Vitro. Journal of Bone and Mineral Research. 18(2). 204–212. 67 indexed citations
6.
Rogers, Michael J., Sharon Gordon, Helena L. Benford, et al.. (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88(S12). 2961–2978. 720 indexed citations breakdown →
7.
Mönkkönen, Hannu, et al.. (2000). Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography–electrospray ionisation mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 738(2). 395–403. 34 indexed citations
8.
Rogers, Michael J., Sharon Gordon, Helena L. Benford, et al.. (2000). Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 88(S12). 2961–2978. 571 indexed citations breakdown →
9.
Salminen, Antero, Michael J. Rogers, Julie C. Frith, et al.. (1999). Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite. European Journal of Pharmaceutical Sciences. 8(2). 109–118. 88 indexed citations
10.
Benford, Helena L., Julie C. Frith, Seppo Auriola, Jukka Mönkkönen, & Michael J. Rogers. (1999). Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmacological Classes of Bisphosphonate Drugs. Molecular Pharmacology. 56(1). 131–140. 5 indexed citations
11.
Rogers, Michael J., Julie C. Frith, Steven P. Luckman, et al.. (1999). Molecular mechanisms of action of bisphosphonates. Bone. 24(5). 73S–79S. 181 indexed citations
12.
Benford, Helena L., Julie C. Frith, Seppo Auriola, Jukka Mönkkönen, & Michael J. Rogers. (1999). Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmacological Classes of Bisphosphonate Drugs. Molecular Pharmacology. 56(1). 131–140. 207 indexed citations
13.
Russell, R.G.G., Michael J. Rogers, Julie C. Frith, et al.. (1999). The pharmacology of bisphosphonates and new insights into their mechanisms of action. Journal of Bone and Mineral Research. 14(S2). 53–65. 206 indexed citations
14.
Mönkkönen, Jukka, et al.. (1999). Effects of Bisphosphonates on the Inflammatory Processes of Activated Macrophages. Phosphorus, sulfur, and silicon and the related elements. 144(1). 321–324. 6 indexed citations
15.
Auriola, Seppo, et al.. (1997). Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography–electrospray mass spectrometry. Journal of Chromatography B Biomedical Sciences and Applications. 704(1-2). 187–195. 85 indexed citations
16.
Frith, Julie C., Jukka Mönkkönen, G. Michael Blackburn, R.G.G. Russell, & Michael J. Rogers. (1997). Clodronate and Liposome-Encapsulated Clodronate Are Metabolized to a Toxic ATP Analog, Adenosine 5′-(β,γ-Dichloromethylene) Triphosphate, by Mammalian Cells In Vitro. Journal of Bone and Mineral Research. 12(9). 1358–1367. 356 indexed citations
17.
Frith, Julie C., C.P. Sibley, & Barbara J. Ward. (1986). Histochemical localization of phosphotases in the pig placenta: I. Non-specific phosphatases and their relation to uteroferrin. Placenta. 7(1). 17–25. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026